CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer

Small cell lung cancer (SCLC) is characterised by high relapse rates. Tumour-initiating cells (TICs) are responsible for drug resistance and recurrence of cancer. Rovalpituzumab tesirine (Rova-T), a potent humanised antibody–drug conjugate, selectively targets delta-like protein 3, which is highly e...

全面介紹

Na minha lista:
書目詳細資料
發表在:Br J Cancer
Main Authors: Lindner, Daniel J., Wildey, Gary, Parker, Yvonne, Dowlati, Afshin, Stark, George R., De, Sarmishtha
格式: Artigo
語言:Inglês
出版: Nature Publishing Group UK 2020
主題:
Brief Communication
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7921085/
https://ncbi.nlm.nih.gov/pubmed/33257843
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-01192-x
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍